Want to see CRNX full AI Analyst Report?
CRNX Stock Chart & Stats
$83.73
<$0.01(0.01%)
At close: 4:00 PM EDT
$83.73
<$0.01(0.01%)
Day’s Range― - ―
52-Week Range$28.73 - $84.76
Previous CloseN/A
Volume9.77K
Average Volume (3M)6.12M
Market Cap
$8.98B
Enterprise Value$2.79K
Total Cash (Recent Filing)$1.21B
Total Debt (Recent Filing)$47.19M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Nov 17, 2026EPS Estimate
-1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.05
Shares Outstanding106,065,230
10 Day Avg. Volume4,155,075
30 Day Avg. Volume6,124,660
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)4.41
Price to Sales (P/S)568.91
P/FCF Ratio-11.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$85.56Price Target Upside2.18% Upside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)-4.66
Revenue Forecast (FY)$68.59M
Bulls Say, Bears Say
Bulls Say
Early Commercial TractionInitial sales and patient additions demonstrate that Palsonify is gaining commercial adoption. Continued enrollment growth can build a durable revenue base, while early launch performance provides validation for Crinetics’ commercialization strategy.
Pipeline And Efficacy MomentumAn active late-stage and mid-stage pipeline gives Crinetics multiple opportunities to expand beyond its initial product. Positive efficacy data may support payer discussions, physician adoption and future indications in endocrine diseases.
Strong Balance Sheet And RunwaySubstantial liquidity and low leverage provide flexibility to fund commercialization and clinical development without immediate balance-sheet pressure. The projected runway also allows the company to pursue multiple pivotal readouts.
Bears Say
Large Ongoing LossesThe company remains far from sustainable profitability despite revenue growth. Large losses relative to revenue show that current commercial scale does not yet cover development and operating costs, leaving long-term earnings dependent on execution.
Heavy Cash Burn And Funding NeedsPersistent cash outflows indicate a high funding requirement as Crinetics expands its pipeline and commercial infrastructure. Even with substantial liquidity, continued burn could reduce financial flexibility or increase reliance on external capital.
Adoption And Reimbursement ConstraintsIncomplete reimbursement and limited appointment capacity can slow patient conversion and delay the revenue ramp. These operational barriers may persist as the company expands access, making commercial growth dependent on payer and provider execution.
Crinetics Pharmaceuticals News
CRNX FAQ
What was Crinetics Pharma’s price range in the past 12 months?
Crinetics Pharma lowest stock price was $28.73 and its highest was $84.76 in the past 12 months.
What is Crinetics Pharma’s market cap?
Crinetics Pharma’s market cap is $8.98B.
When is Crinetics Pharma’s upcoming earnings report date?
Crinetics Pharma’s upcoming earnings report date is Nov 17, 2026 which is in 91 days.
How were Crinetics Pharma’s earnings last quarter?
Crinetics Pharma released its earnings results on Aug 03, 2026. The company reported -$1.14 earnings per share for the quarter, beating the consensus estimate of -$1.179 by $0.039.
Is Crinetics Pharma overvalued?
According to Wall Street analysts Crinetics Pharma’s price is currently Undervalued.
Does Crinetics Pharma pay dividends?
Crinetics Pharma does not currently pay dividends.
What is Crinetics Pharma’s EPS estimate?
Crinetics Pharma’s EPS estimate is -1.16.
How many shares outstanding does Crinetics Pharma have?
Crinetics Pharma has 106,065,230 shares outstanding.
What happened to Crinetics Pharma’s price movement after its last earnings report?
Crinetics Pharma reported an EPS of -$1.14 in its last earnings report, beating expectations of -$1.179. Following the earnings report the stock price went up 0.119%.
Which hedge fund is a major shareholder of Crinetics Pharma?
Currently, no hedge funds are holding shares in CRNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crinetics Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$85.56 (2.18% Upside)
$85.56 (2.18% Upside)
Blogger Sentiment
Neutral
CRNX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
175.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.51%
Trailing 12-Months
Company Description
Crinetics Pharma
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
CRNX Company Deck
CRNX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong early commercial launch for Palsonify with meaningful patient additions, encouraging reimbursement progress (≈70% reimbursed, >60% coverage), expanding prescriber footprint and robust pipeline advancement, all supported by a strong balance sheet. Offsetting these positives are elevated and rising R&D and operating expenses, limited disclosure of certain commercial conversion metrics, a remaining reimbursement gap (~30% of patients), appointment‑driven adoption constraints, and no firm timelines provided for several key pivotal readouts or international revenue. On balance, the positives around launch momentum, payer traction, prescriber growth and cash runway outweigh the operational and disclosure limitations.View all CRNX earnings summariesCRNX Stock 12 Month Forecast
Average Price Target
$85.56
▲(2.18% Upside)
Technical Analysis
Ownership Overview
1.96% Insiders
40.86% Mutual Funds
39.21% Other Institutional Investors
1.35% Public Companies and
Individual Investors